Dr. Sant P. Chawla on Trabectedin for the Treatment of Mesenchymal Chondrosarcoma
Sant P. Chawla, MD, director, Sarcoma Oncology Center, discusses the potential for trabectedin as treatment of mesenchymal chondrosarcoma.
Sant P. Chawla, MD, director, Sarcoma Oncology Center, discusses the potential for trabectedin as treatment of mesenchymal chondrosarcoma.
Mesenchymal chondrosarcoma is a very rare disease that often has a lot of potential to metastasize, Chawla says.
In this small study of fewer than 20 patients, some patients had previously failed standard chemotherapy and trabectedin did control disease in some of those patients for up to two years.
Moving forward, Chawla says, there will first need to be collaboration between institutions and pharmaceutical companies to determine if similar results have been seen before.
Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma
October 7th 2024A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.
Read More
